SCHEMBL2945669

SCHEMBL2945669

CCN(CCO)c1ccc(C=O)c(C)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.50
L3MBTL1 Q9Y468 3/20 0.50
MAPT P10636 10/20 0.43
S100B P04271 1/20 0.42
ALDH3A1 P30838 1/20 0.42
ALDH1A3 P47895 1/20 0.42
KMT2A Q03164 5/20 0.42
MEN1 O00255 3/20 0.42
KDM4E B2RXH2 3/20 0.42
HPGD P15428 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
IGLV6-57 P01721 2/20 0.41
RAB9A P51151 4/20 0.40
NPC1 O15118 3/20 0.40
PSMD14 O00487 1/20 0.40
MITF O75030 1/20 0.40
LMNA P02545 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
MAPK1 P28482 2/20 0.40
GAA P10253 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8024385 0.92 MAPT (0.46) ALDH1A1L3MBTL1MAPTS100BALDH3A1
SCHEMBL2845181 0.87 ALDH1A1 (0.63) ALDH1A1L3MBTL1MAPTS100BALDH3A1
SCHEMBL11183654 0.85 ALDH1A1 (0.50) ALDH1A1L3MBTL1MAPTS100BALDH3A1
SCHEMBL61553 0.85 ALDH1A1 (0.50) ALDH1A1L3MBTL1MAPTKMT2AMEN1
SCHEMBL9513863 0.85 ALDH1A1 (0.50) ALDH1A1L3MBTL1MAPTS100BALDH3A1
SCHEMBL8017515 0.85 ALDH1A1 (0.50) ALDH1A1L3MBTL1MAPTS100BALDH3A1
SCHEMBL10119054 0.83 ALDH1A1 (0.41) ALDH1A1L3MBTL1MAPTS100BALDH3A1
SCHEMBL2324164 0.82 ALDH1A1 (0.43) ALDH1A1L3MBTL1MAPTKMT2AMEN1
SCHEMBL24991896 0.81 CYBB (0.39) ALDH1A1L3MBTL1MAPTKDM4ERAB9A
SCHEMBL13182636 0.81 ALDH1A1 (0.78) ALDH1A1L3MBTL1MAPTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115160752-B Polylactic acid composite material for mulching film and application thereof 山西生物质新材料产业研究院有限公司 2023-08-01 CN claimed
CN-115160752-A Polylactic acid composite material for mulching film and application thereof 山西生物质新材料产业研究院有限公司 2022-10-11 CN claimed
EP-2460855-A2 Oxygen scavenging compositions and packaging comprising said compositions Constar International Inc. (US) 2012-06-06 EP claimed
US-20090278087-A1 Oxygen Scavenging Compositions and Packaging Comprising Said Compositions CONSTAR INTERNATIONAL, INC (US) 2009-11-12 US claimed
EP-1848659-A2 OXYGEN SCAVENGING COMPOSITIONS AND PACKAGING COMPRISING SAID COMPOSITIONS Constar International Inc. (US) 2007-10-31 EP claimed
WO-2006088889-A2 OXYGEN SCAVENGING COMPOSITIONS AND PACKAGING COMPRISING SAID COMPOSITIONS CONSTAR INTERNATIONAL, INC. (US) 2006-08-24 WO claimed
US-20060180790-A1 polyesters; melt polymerization; packaging CONSTAR INTERNATIONAL INC. (US) 2006-08-17 US claimed
CN-114249670-B Organic compound with large pi conjugated surface, and preparation method and application thereof 郑州轻工业大学 2023-10-31 CN disclosed
CN-115160752-B Polylactic acid composite material for mulching film and application thereof 山西生物质新材料产业研究院有限公司 2023-08-01 CN disclosed
CN-115160752-A Polylactic acid composite material for mulching film and application thereof 山西生物质新材料产业研究院有限公司 2022-10-11 CN disclosed
CN-114249670-A Organic compound with large pi conjugated surface and preparation method and application thereof 郑州轻工业大学 2022-03-29 CN disclosed
US-8721920-B2 Oxygen scavenging compositions and packaging comprising said compositions PLASTIPAK PACKAGING, INC. (US) 2014-05-13 US disclosed
EP-1848659-B1 OXYGEN SCAVENGING COMPOSITIONS AND PACKAGING COMPRISING SAID COMPOSITIONS CONSTAR INT INC (US) 2013-03-20 EP disclosed
US-20060180790-A1 polyesters; melt polymerization; packaging CONSTAR INTERNATIONAL INC. (US) 2006-08-17 US disclosed
EP-1687641-A2 TREATING NEUROPATHIC PAIN WITH NEUROPEPTIDE FF RECEPTOR 2 AGONISTS Acadia Pharmaceuticals Inc. (US) 2006-08-09 EP disclosed
US-20050136444-A1 Treating neuropathic pain with neuropeptide FF receptor 2 agonists ACADIA PHARMACEUTICALS INC. 2005-06-23 US disclosed
WO-2005031000-A2 TREATING NEUROPATHIC PAIN WITH NEUROPEPTIDE FF RECEPTOR 2 AGONISTS ACADIA PHARMACEUTICALS INC. (US) 2005-04-07 WO disclosed
EP-0453395-B1 Pressure sensitive recording material CIBA GEIGY AG (CH) 1995-11-02 EP disclosed
US-5254522-A Pressure-sensitive or heat-sensitive recording material CIBA-GEIGY CORPORATION (US) 1993-10-19 US disclosed
EP-0453395-A1 Pressure sensitive recording material CIBA-GEIGY AG (CH) 1991-10-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090278087-A1 Oxygen Scavenging Compositions and Packaging Comprising Said Compositions LPO, GPX4, PRDX3 ALDH1A1 548/4885L3MBTL1 248/4885MAPT 3540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.